A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients wi1
Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TILs1
The Hospital Clínic-IDIBAPS has developed the first CAR T-cell therapy in Europe to treat multiple myeloma, the second most common type of blood canc1
Interview with Dr. Manel Juan, head of the Immunology Service
The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved CAR-T ARI-0001, developed by Hospital Clínic, as and advanced therapy drug o1
Immuneel Therapeutics Private Limited (Immuneel) today announced that it has entered into a multi-asset collaboration and licensing agreement with Ho1
Hospital Clínic de Barcelona-IDIBAPS and Cellnex have today signed an agreement to launch a multicentre research project that will allow better under1
Hospital Clínic – IDIBAPS (Barcelona) has founded Gyala Therapeutics, a new spin-off company focused on developing new CAR-T therapies for treating h1
